MT Group’s Deep Expertise in Liquid Biopsy
MT Group’s founders pioneered liquid biopsy before the field had its name. In the late 1980s-1990s, they developed and commercialized a circulating tumor cell (CTC)-based assay for blood and bone marrow, analyzing over 30,000 specimens in their CLIA-certified laboratory under a laboratory-developed test. This foundational experience in detecting rare cancer biomarkers in complex biofluids has shaped MT Group’s program that has supported liquid biopsy development since the company’s founding in 2003.
Today, MT Group works with nearly all major public liquid biopsy companies as well as emerging startups, providing human blood procurement and biospecimen collection services that advance early cancer detection, minimal residual disease monitoring, and therapeutic guidance assay development. We collect blood, plasma, urine, and matched tissue specimens from diverse cancer populations and high-risk control cohorts such as subjects with precancerous conditions, family histories, or other risk factors. Our deep understanding of liquid biopsy workflows, analytical challenges, and clinical utility requirements positions us as a strategic partner, not just a vendor. We contribute meaningfully during study design phase, helping customers build collections that address the unique technical and clinical validation needs of their liquid biopsy platforms.
MT Group’s Deep Expertise in Liquid Biopsy
MT Group’s founders pioneered liquid biopsy before the field had its name. In the late 1980s-1990s, they developed and commercialized a circulating tumor cell (CTC)-based assay for blood and bone marrow, analyzing over 30,000 specimens in their CLIA-certified laboratory under a laboratory-developed test. This foundational experience in detecting rare cancer biomarkers in complex biofluids has shaped MT Group’s program that has supported liquid biopsy development since the company’s founding in 2003.
Today, MT Group works with nearly all major public liquid biopsy companies as well as emerging startups, providing human blood procurement and biospecimen collection services that advance early cancer detection, minimal residual disease monitoring, and therapeutic guidance assay development. We collect blood, plasma, urine, and matched tissue specimens from diverse cancer populations and high-risk control cohorts such as subjects with precancerous conditions, family histories, or other risk factors. Our deep understanding of liquid biopsy workflows, analytical challenges, and clinical utility requirements positions us as a strategic partner, not just a vendor. We contribute meaningfully during study design phase, helping customers build collections that address the unique technical and clinical validation needs of their liquid biopsy platforms.
Liquid Biopsy Populations, Applications, and Biospecimens
Patient Populations
MT Group provides human blood procurement across nearly all solid tumor types as well as healthy and at-risk control populations essential for liquid biopsy assay validation. An example could be collecting both breast cancer patients as well as ductal carcinoma in situ (DCIS) and dense breast subjects. These control populations enable researchers to establish assay specificity and distinguish true cancer signal from confounding conditions.
Assay Applications
We support liquid biopsy development across multiple clinical applications. For early cancer detection assays, we often collect both cancer and control cohorts. Alternatively, we regularly collect subjects at a specific cancer screening timepoint such as at colonoscopy or mammogram, providing scans and pathology reports for health status documentation. For therapeutic guidance applications, we collect pre-treatment specimens and outcome information to elucidate response to therapy. For minimal residual disease (MRD) monitoring, we longitudinally collect specimens throughout the patient journey—including post-surgical, on-adjuvant therapy, and post-therapy timepoints—providing critical response-to-therapy information that validates assay clinical utility.
Biospecimen Types
MT Group supports tumor-informed approaches requiring matched FFPE tissue and blood collections as well as tumor-agnostic assays that require blood-only protocols. Urine and other biofluids are becoming increasingly utilized in liquid biopsy development and we regularly incorporate these specimen types into collection protocols.
Why Liquid Biopsy Companies Choose MT Group
Deep Domain Expertise: With over 30 years of history in the liquid biopsy space, we understand the field from the inside out. This expertise is particularly valuable for startups navigating their first validation studies—we help design high-impact collections; asking the right questions about populations, timepoints, biospecimen processing & handling, and clinical data to maximize the utility of every specimen collected.
Proven Collection Sites: We work with established collection sites that execute the refined protocols that we’ve developed through hundreds of liquid biopsy studies. These sites understand the critical importance of following detailed inclusion and exclusion criteria, precise biospecimen processing protocols, and comprehensive clinical data requirements. Our sites implement protocols with discipline and attention to detail, eliminating the trial-and-error phase that can compromise specimen quality.
Exceptional Study Execution: Our project management team excels at running complex liquid biopsy collections with highly specific inclusion and exclusion criteria, ensuring sites follow precise enrollment parameters. For longitudinal collections that track patients through treatment and follow-up, we regularly achieve 90%+ retention rates for subjects who don't pass away or enter hospice care. This meticulous execution ensures your collections deliver the complete, high-quality datasets necessary for robust assay development.
Quality Assurance & Services
Ethical procurement, rigorous reviews and full traceability ensure specimens you can trust.
IRB‑Approved Collections
All MT Group tissue collections are conducted under Institutional Review Board (IRB) approval, ensuring ethical procurement and full regulatory compliance. This commitment guarantees that every specimen is collected with proper informed consent and adheres to the highest standards of human subject research protections.
Quality Review
All blood products undergo a comprehensive quality review by the MT Group quality team prior to release. This systematic inspection includes hemolysis evaluation to ensure product integrity, verification of appropriate fill volumes to confirm compliance with established specifications, and thorough labeling examination to verify accuracy and completeness. This multi-point quality assessment serves as a critical control measure to ensure that only products meeting established quality standards are released.
Specimen Replacement Guarantee
MT Group stands behind the quality of every specimen delivered. If any tissue fails to meet specifications due to shipping issues, handling concerns, or quality parameters, we will replace the specimen at no additional cost, ensuring your research timelines and budgets remain on track.
Chain of Custody & Documentation
Comprehensive documentation accompanies each specimen, including collection details, processing protocols, storage conditions, and pathology reports. This complete chain of custody provides full traceability and the clinical context necessary for robust, reproducible research outcomes.
Why Leading Researchers Choose MT Group
Contact MT Group
Complete the form below to discuss your tissue requirements with our experts.
No obligation consultation. Response within one business day.
